
Risk of Ebola emergence mapped via University of Oxford
A clinical trial conducted in the midst of an Ebola epidemic in the Democratic Republic of Congo (DRC) has identified two new drugs that can dramatically cut mortality from the disease, and both are being immediately offered to all patients in an effort to control the country’s worst ever outbreak.
The Pamoja Tulinde Maisha (“together save lives” in Swahili) trial began last November, in four towns stricken by the outbreak. It compared four potential treatments proposed by four different companies: ZMapp, remdesivir, mAb114, and REGN-EB3.
Preliminary data has convinced the trial’s monitoring board to stop the study and randomise all remaining patients to either mAb114 or REGN-EB3.1
Data from the first 499 patients showed that REGN-EB3 had met early stopping criteria, and mAb114 was not far behind. Among all patients who took the drugs, those treated with REGN-EB3 had a mortality rate of 29%, while those who got mAb-114 had a mortality rate of 34%.
Patients treated with ZMapp, the best known Ebola treatment candidate, which was used in the west African epidemic of 2014, had a 49% mortality rate. Those treated with the antiviral remdesivir had a 53% mortality rate.
More than 75% of those who received no treatment have died in the epidemic, which has killed nearly 1900 people out of 2831 confirmed cases.
Researchers believe they can improve outcomes further in patients who are reached early in the course of infection. Among such patients, mortality rates were 6% with REGN-EB3, 11% with mAb114, 24% with ZMapp, and 33% with remdesivir.
Both REGN-EB3 and mAb114, like ZMapp, are monoclonal antibodies, proteins that bind to other proteins on the outer shell of the Ebola virus, which it uses to attach itself to human cells.
Regeneron Pharmaceuticals made REGN-EB3, a cocktail of three such proteins, using antibodies from “humanised” mice infected with Ebola.
The US National Institute of Allergy and Infectious Diseases created mAb114 using antibodies isolated from the blood of a survivor of a 1995 outbreak in DRC. It will be developed by Ridgeback Therapeutics.
“From now on, we will no longer say that Ebola is incurable,” said Jean-Jacques Muyembe-Tamfum, director of the DRC’s Institut National de Recherche Biomédicale, which oversaw the trial. Full results are expected by early October and will appear in a peer reviewed journal soon thereafter.
Muyembe, who was part of the team that discovered the Ebola virus 43 years ago, and who in 1995 became the first doctor to harvest antibodies from survivors, told a press conference that the news of effective treatments would reinvigorate the campaign to end the current outbreak, which has struggled against deep local suspicion in a region plagued by insecurity.
“People think that if you enter a treatment centre, you’ll leave in a coffin,” said Muyembe. But with such high survival rates in the newly infected, he said, “We have a great message: a treatment centre is a place where you can recover and that you leave alive.”
Learn more: Two Ebola treatments halve deaths in trial in DRC outbreak
The Latest on: Ebola
via Google News
The Latest on: Ebola
- Supply chain delays affect planned stockpile of Ebola vaccineson January 19, 2021 at 5:02 pm
Supply chain delays must be addressed to speed up creation of a stockpile of vaccines against deadly Ebola disease, researchers say.
- International health organizations establish global Ebola vaccine stockpileon January 18, 2021 at 8:42 pm
The four leading international health and humanitarian organizations announced today the establishment of a global Ebola vaccine stockpile to ensure outbreak response.
- Ebola vaccines stockpiled against future outbreakson January 12, 2021 at 6:57 am
The World Health Organization and partners said Tuesday they are creating a global stockpile of Ebola vaccines to help stamp out future outbreaks. In a statement, WHO, ...
- UNICEF, WHO, IFRC and MSF announce the establishment of a global Ebola vaccine stockpile [EN/AR/RU]on January 11, 2021 at 4:01 pm
Arabic News and Press Release on World about Disaster Management, Health and Epidemic; published on 12 Jan 2021 by IFRC, MSF and 3 other organizations ...
- WHO, Partners Announce Ebola Vaccine Stockpileon January 11, 2021 at 4:00 pm
Parts of the world ravaged by outbreaks of Ebola can now heave a small sigh of relief thanks to the stockpile of vaccine, the International Coordinating Group (ICG) announced Monday. The single-dose ...
- UNICEF, WHO, IFRC and MSF announce the establishment of a global Ebola vaccine stockpileon January 11, 2021 at 3:26 pm
The four leading international health and humanitarian organizations announced today the establishment of a global Ebola vaccine stockpile to ensure outbreak response.
- Disease X: Doctor who discovered Ebola warns of deadly viruses yet to comeon January 4, 2021 at 11:26 pm
They are waiting for the results of a test for Ebola. The patient can only communicate with her relatives through a clear plastic observation window. Her identity is secret, to protect her from ...
- Colonization Fueled Ebola: Dr. Paul Farmer on “Fevers, Feuds & Diamonds” & Lessons from West Africaon January 1, 2021 at 8:38 am
We continue our conversation with medical anthropologist Dr. Paul Farmer, whose new book, “Fevers, Feuds, and Diamonds,” tells the story of his efforts to fight Ebola in 2014 and how the ...
- Hunting for ‘Disease X’: The doctor who discovered Ebola warns of deadly viruses yet to comeon December 24, 2020 at 2:08 pm
They are waiting for the results of a test for Ebola. The patient can only communicate with her relatives through a clear plastic observation window. Her identity is secret, to protect her from ...
- Doctor who discovered Ebola warns of new deadly diseaseson December 23, 2020 at 5:30 am
They are waiting for the results of a test for Ebola. The patient can only communicate with her relatives through a clear plastic observation window. Her identity is secret, to protect her from ...
via Bing News